-
2
-
-
0026636032
-
Multimodality treatment of stage IIIA non-small-cell lung carcinoma: A critical review of the literature and strategies for future research
-
Strauss GM, Langer MP, Elias AD, et al. Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research. J Clin Oncol 1992;10:829-838.
-
(1992)
J Clin Oncol
, vol.10
, pp. 829-838
-
-
Strauss, G.M.1
Langer, M.P.2
Elias, A.D.3
-
3
-
-
1342268525
-
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
-
Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
-
(2004)
J Clin Oncol
, vol.22
, pp. 330-353
-
-
Pfister, D.G.1
Johnson, D.H.2
Azzoli, C.G.3
-
4
-
-
0032858243
-
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
-
Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2692-2699
-
-
Furuse, K.1
Fukuoka, M.2
Kawahara, M.3
-
5
-
-
80054072961
-
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410
-
Curran WJ Jr., Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-1460.
-
(2011)
J Natl Cancer Inst
, vol.103
, pp. 1452-1460
-
-
Curran, W.J.1
Paulus, R.2
Langer, C.J.3
-
6
-
-
20544435485
-
Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer
-
Belani CP, Wang W, Johnson DH, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005;23:3760-3767.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3760-3767
-
-
Belani, C.P.1
Wang, W.2
Johnson, D.H.3
-
7
-
-
0030463425
-
Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer
-
Choy H, Akerly W, Safran H, et al. Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Semin Oncol 1996;23(Suppl 16):117-119.
-
(1996)
Semin Oncol
, vol.23
, pp. 117-119
-
-
Choy, H.1
Akerly, W.2
Safran, H.3
-
8
-
-
34248651350
-
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B
-
Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-1704.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1698-1704
-
-
Vokes, E.E.1
Herndon, J.E.2
Kelley, M.J.3
-
9
-
-
0038688474
-
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504
-
Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004-2010.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2004-2010
-
-
Gandara, D.R.1
Chansky, K.2
Albain, K.S.3
-
10
-
-
0037102282
-
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019
-
Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002;20:3454-3460.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3454-3460
-
-
Albain, K.S.1
Crowley, J.J.2
Turrisi, A.T.3
-
11
-
-
33644701684
-
The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer
-
Edelman MJ. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Clin Lung Cancer 2005;7(Suppl 2):S64-S66.
-
(2005)
Clin Lung Cancer
, vol.7
, pp. S64-S66
-
-
Edelman, M.J.1
-
12
-
-
79951702955
-
Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives
-
Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011;11:239-253.
-
(2011)
Curr Cancer Drug Targets
, vol.11
, pp. 239-253
-
-
Chen, D.1
Frezza, M.2
Schmitt, S.3
-
13
-
-
33144469102
-
The proteasome and proteasome inhibitors in cancer therapy
-
Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006;46:189-213.
-
(2006)
Annu Rev Pharmacol Toxicol
, vol.46
, pp. 189-213
-
-
Voorhees, P.M.1
Orlowski, R.Z.2
-
14
-
-
14544303662
-
Proteasome inhibition as a novel therapeutic target in human cancer
-
Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-639.
-
(2005)
J Clin Oncol
, vol.23
, pp. 630-639
-
-
Rajkumar, S.V.1
Richardson, P.G.2
Hideshima, T.3
-
15
-
-
33750945704
-
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
-
Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5025-5033.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5025-5033
-
-
Fanucchi, M.P.1
Fossella, F.V.2
Belt, R.3
-
16
-
-
84899061436
-
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: A Wisconsin Oncology Network Phase II study
-
Hoang T, Campbell TC, Zhang C, et al. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest New Drugs 2014;32:195-199.
-
(2014)
Invest New Drugs
, vol.32
, pp. 195-199
-
-
Hoang, T.1
Campbell, T.C.2
Zhang, C.3
-
17
-
-
68349122406
-
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer
-
Lynch TJ, Fenton D, Hirsch V, et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2009;4:1002-1009.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 1002-1009
-
-
Lynch, T.J.1
Fenton, D.2
Hirsch, V.3
-
18
-
-
77952548567
-
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer
-
Scagliotti GV, Germonpre P, Bosquee L, et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010;68:420-426.
-
(2010)
Lung Cancer
, vol.68
, pp. 420-426
-
-
Scagliotti, G.V.1
Germonpre, P.2
Bosquee, L.3
-
19
-
-
79551527647
-
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: A California cancer consortium trial
-
Lara PN Jr., Longmate J, Rekamp K, et al. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer 2011;12:33-37.
-
(2011)
Clin Lung Cancer
, vol.12
, pp. 33-37
-
-
Lara, P.N.1
Longmate, J.2
Rekamp, K.3
-
20
-
-
84861332378
-
Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer
-
Piperdi B, Walsh WV, Bradley K, et al. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol 2012;7:1032-1040.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 1032-1040
-
-
Piperdi, B.1
Walsh, W.V.2
Bradley, K.3
-
21
-
-
61549138750
-
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II Southwest Oncology Group Study (S0339)
-
Davies AM, Chansky K, Lara PN Jr, et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009;4:87-92.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 87-92
-
-
Davies, A.M.1
Chansky, K.2
Lara, P.N.3
-
22
-
-
33845363835
-
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies
-
Ma C, Mandrekar SJ, Alberts SR, et al. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 2007;59:207-215.
-
(2007)
Cancer Chemother Pharmacol
, vol.59
, pp. 207-215
-
-
Ma, C.1
Mandrekar, S.J.2
Alberts, S.R.3
-
23
-
-
0035341494
-
Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB
-
Russo SM, Tepper JE, Baldwin AS, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001;50:183-193.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.50
, pp. 183-193
-
-
Russo, S.M.1
Tepper, J.E.2
Baldwin, A.S.3
-
24
-
-
77649180962
-
Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in stage III non-small cell lung cancer
-
Edelman MJ, Burrows W, Krasna MJ, et al. Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in stage III non-small cell lung cancer. Lung Cancer 2010;68:84-88.
-
(2010)
Lung Cancer
, vol.68
, pp. 84-88
-
-
Edelman, M.J.1
Burrows, W.2
Krasna, M.J.3
-
25
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
26
-
-
0024452804
-
Design and analysis of phase I clinical trials
-
Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989;45:925-937.
-
(1989)
Biometrics
, vol.45
, pp. 925-937
-
-
Storer, B.E.1
-
27
-
-
0000885136
-
Nonparametric estimation from incomplete observations
-
Kaplan EL, Paul M. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;25:17-24.
-
(1958)
J Am Stat Assoc
, vol.25
, pp. 17-24
-
-
Kaplan, E.L.1
Paul, M.2
-
28
-
-
84896085964
-
Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multicenter phase II study investigating
-
Van den Heuvel MM, Uyterlinde W, Vincent AD, et al. Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multicenter phase II study investigating. Radiother Oncol 2014;110:126-131.
-
(2014)
Radiother Oncol
, vol.110
, pp. 126-131
-
-
Van Den Heuvel, M.M.1
Uyterlinde, W.2
Vincent, A.D.3
-
29
-
-
84858857700
-
Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer
-
Lind JS, Senan S, Smit EF. Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer. J Clin Oncol 2012;30:e104-e108.
-
(2012)
J Clin Oncol
, vol.30
, pp. e104-e108
-
-
Lind, J.S.1
Senan, S.2
Smit, E.F.3
-
30
-
-
76149123903
-
A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer
-
Center B, Petty WJ, Ayala D, et al. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol 2010;5:69-74.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 69-74
-
-
Center, B.1
Petty, W.J.2
Ayala, D.3
-
31
-
-
79959587751
-
Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: The NEAR trial
-
Jensen AD, Munter MW, Bischoff HG, et al. Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer 2011;117:2986-2994.
-
(2011)
Cancer
, vol.117
, pp. 2986-2994
-
-
Jensen, A.D.1
Munter, M.W.2
Bischoff, H.G.3
-
32
-
-
44649168832
-
A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study
-
Hughes S, Liong J, Miah A, et al. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol 2008;3:648-651.
-
(2008)
J Thorac Oncol
, vol.3
, pp. 648-651
-
-
Hughes, S.1
Liong, J.2
Miah, A.3
-
33
-
-
0032905030
-
Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB
-
Wang CY, Cusack JC Jr, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5:412-417.
-
(1999)
Nat Med
, vol.5
, pp. 412-417
-
-
Wang, C.Y.1
Cusack, J.C.2
Liu, R.3
-
34
-
-
3042771639
-
The p53 protein family and radiation sensitivity: Yes or no?
-
Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: yes or no? Cancer Metastasis Rev 2004;23:237-257.
-
(2004)
Cancer Metastasis Rev
, vol.23
, pp. 237-257
-
-
Cuddihy, A.R.1
Bristow, R.G.2
-
35
-
-
0027258466
-
Thymocyte apoptosis induced by p53-dependent and independent pathways
-
Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
-
(1993)
Nature
, vol.362
, pp. 849-852
-
-
Clarke, A.R.1
Purdie, C.A.2
Harrison, D.J.3
-
36
-
-
9044225527
-
BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
-
Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996;60:23-32.
-
(1996)
J Cell Biochem
, vol.60
, pp. 23-32
-
-
Reed, J.C.1
Miyashita, T.2
Takayama, S.3
-
37
-
-
0001647091
-
Changes in x-ray sensitivity of HeLa cells during the division cycle
-
Terasima T, Tolmach LJ. Changes in x-ray sensitivity of HeLa cells during the division cycle. Nature 1961;190:1210-1211.
-
(1961)
Nature
, vol.190
, pp. 1210-1211
-
-
Terasima, T.1
Tolmach, L.J.2
-
38
-
-
84864685621
-
X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells
-
Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. 1966. Radiat Res 2012;178:AV88-AV101.
-
(1966)
Radiat Res
, vol.178
, pp. AV88-AV101
-
-
Sinclair, W.K.1
Morton, R.A.2
-
39
-
-
0026061699
-
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients
-
Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423.
-
(1991)
J Natl Cancer Inst
, vol.83
, pp. 417-423
-
-
Le Chevalier, T.1
Arriagada, R.2
Quoix, E.3
-
40
-
-
0028909219
-
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer
-
Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 198-205
-
-
Sause, W.T.1
Scott, C.2
Taylor, S.3
-
41
-
-
26444463082
-
Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer
-
Kim DW, Shyr Y, Shaktour B, et al. Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer 2005;50:235-245.
-
(2005)
Lung Cancer
, vol.50
, pp. 235-245
-
-
Kim, D.W.1
Shyr, Y.2
Shaktour, B.3
-
42
-
-
0033067035
-
Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer
-
Choy H, Akerley W, DeVore RF 3rd. Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 1999;26(Suppl 2):36-43.
-
(1999)
Semin Oncol
, vol.26
, pp. 36-43
-
-
Choy, H.1
Akerley, W.2
DeVore, R.F.3
-
43
-
-
80051742422
-
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407
-
Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 2011;29:3120-3125.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3120-3125
-
-
Govindan, R.1
Bogart, J.2
Stinchcombe, T.3
-
44
-
-
20444433230
-
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
-
Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
-
(2005)
N Engl J Med
, vol.352
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.W.3
-
45
-
-
77954134911
-
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial
-
Goy A, Bernstein SH, McDonald A, et al. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma 2010;51:1269-1277.
-
(2010)
Leuk Lymphoma
, vol.51
, pp. 1269-1277
-
-
Goy, A.1
Bernstein, S.H.2
McDonald, A.3
-
46
-
-
84877088158
-
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab
-
Coiffier B, Li W, Henitz ED, et al. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab. Clin Cancer Res 2013;19:2551-2561.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2551-2561
-
-
Coiffier, B.1
Li, W.2
Henitz, E.D.3
|